The Abramson Cancer Center with The Leukemia & Lymphoma Society

Update in

HEMATOLOGIC CANCERS

with Proceedings from International Medical Meetings

FRIDAY, FEBRUARY 7, 2014
8:00 A.M. – 4:15 P.M.

CME/CE - CERTIFIED COURSE

Rittenhouse Hotel
210 West Rittenhouse Square
Philadelphia, PA 19103
Update in Hematologic Cancers
with Proceedings from International Medical Meetings

Friday, February 7, 2014
8:00 A.M. — 4:15 P.M.

Rittenhouse Hotel • 210 West Rittenhouse Square • Philadelphia, PA
For directions and parking go to www.Rittenhousehotel.com. Parking fees are not covered by this course.

Who Should Attend
This course is designed for hematologists, medical and radiation oncologists, primary care physicians, pathologists, hematology/oncology fellows, oncology nurses, oncology social workers, and other healthcare professionals involved in the treatment of patients with blood cancer.

Course Overview
This course is designed to be a comprehensive update of new treatment approaches recently incorporated into patient management, including the different types of hematologic malignancies and how clinicians should evolve therapeutic approaches based on factors, such as tumor classification and response. Penn faculty and invited guest speaker will discuss recent technological advances in blood cancers that will provide a perspective on clinical data presented at major international medical meetings.

Course Objectives
Upon completion of this course, participants should be able to:

• Discuss clinical features, including differential diagnoses, of the various hematologic malignancies
• Describe recent advances in treatment for the various hematologic malignancies
• Summarize the major patient management issues associated with hematologic malignancies
• Identify and manage long-term and late-effects of treatment for hematologic cancers, including bone marrow transplant
• Define the state-of-the-art for genomic analyses for hematologic malignancies
• Apply new strategies for incorporating therapies that target metabolism in blood cancers
AGENDA

8:00 – 8:30AM
Registration and Continental Breakfast

8:30 – 8:40
Welcome and Introduction
Chi Van Dang, MD, PhD
Edward A. Stadtmauer, MD

MORNING SESSIONS
Keynote Speaker
8:40 – 9:00
Precision Medicine: Tailored Treatments for Blood Cancer Patients
D. Gary Gilliland, MD, PhD

CONTROVERSIES AND UPDATES IN MULTIPLE MYELOMA
Moderator: Edward A. Stadtmauer, MD
9:00 – 9:20
Update on MGUS, Smoldering Myeloma and Amyloidosis
Brendan M. Weiss, MD
9:20 – 9:40
Experimental Therapies for Relapsed Myeloma
Dan Vogl, MD
9:40 – 10:00
Latest Transplant Approaches for Myeloma
Edward A. Stadtmauer, MD
10:00 – 10:15
Panel Discussion with Question and Answer Session
Moderator: Edward A. Stadtmauer, MD
Panel:
Dan Vogl, MD
Brendan M. Weiss, MD

10:15 – 10:30
BREAK

TRANSPANT AND CELLULAR THERAPIES
Moderator: David L. Porter, MD
10:30 – 10:50
Graft versus Host Disease
Ran Reshef, MD
10:50 – 11:10
Cellular Therapy for Blood Cancers
David L. Porter, MD
11:10 – 11:30
Emerging Treatment Options for Myelodysplastic Syndromes
Noelle V. Frey, MD
11:30 – 11:45
Panel Discussion with Question and Answer Session
Moderator: David L. Porter, MD
Panel: Ran Reshef, MD
Noelle V. Frey, MD
11:45 – 12:45
LUNCH

UPDATES ON TREATMENT STRATEGIES IN LEUKEMIA
Moderator: Selina Luger, MD
12:45 – 1:05
From Omics to Clinics: Using New Technologies for the Treatment of Blood Cancer
Jennifer J.D. Morrissette, PhD
1:05 – 1:25
Updates in Treatment Strategies for Leukemia
Selina Luger, MD
1:25 – 1:45
Experimental Therapies for Leukemia
Alexander Perl, MD
1:45 – 2:05
Latest Update in Myeloproliferative Disease
Elizabeth O. Hexner, MD
2:05 – 2:25
Panel Discussion with Question and Answer Session
Moderator: Selina Luger, MD
Panel:
Jennifer J.D. Morrissette, PhD
Alexander Perl, MD
Elizabeth O. Hexner, MD
2:25 – 2:40
BREAK

NEW THERAPIES AND CURRENT MANAGEMENT OF LYMPHOMAS
Moderator: Stephen J. Schuster, MD
2:40 – 3:00
New Therapies and Current Management of Lymphomas
Stephen J. Schuster, MD
3:00 – 3:20
Therapeutic Advances in Hodgkin Lymphoma
Jakub Svoboda, MD
3:20 – 3:40
New Therapies for Mantle Cell and T-cell Lymphomas
Sunita D. Nasta, MD
3:40 – 4:00
Chronic Lymphocytic Leukemia
Anthony R. Mato, MD, MSCE
4:00 – 4:15
Panel Discussion with Question and Answer Session
Moderator: Stephen J. Schuster, MD
Panel: Jakub Svoboda, MD
Sunita D. Nasta, MD
Anthony R. Mato, MD, MSCE
4:15
Evaluation & Adjourn
Penn Medicine Faculty

Course Director
Edward A. Stadtmauer, MD
Professor of Medicine
Chief, Hematologic Malignancies Section
Division of Hematology Oncology
Co-Leader, Hematologic Malignancies Research Program
Abramson Cancer Center

Course Co-Directors
Selina Luger, MD
Professor, Medicine
Division of Hematology Oncology
Director, Leukemia Program

David L. Porter, MD
Jodi Fisher Horowitz Professor in Leukemia Care Excellence
Director, Blood and Marrow Transplantation and Cellular Therapeutics Program

Stephen J. Schuster, MD
Robert and Margarita Louis-Dreyfus Associate Professor of Chronic Lymphocytic Leukemia and Lymphoma
Division of Hematology Oncology
Director, Lymphoma Program and Lymphoma Translational Research

Faculty
Chi Van Dang, MD, PhD
Abramson Cancer Center
Director’s Professor of Medicine
Director, Abramson Cancer Center
Director, Abramson Family Cancer Research Institute

Noelle V. Frey, MD
Assistant Professor, Medicine
Division of Hematology Oncology

D. Gary Gilliland, MD, PhD
Vice Dean and Vice President for Precision Medicine

Elizabeth O. Hexner, MD
Assistant Professor, Medicine
Division of Hematology Oncology

Jennifer J.D. Morrissette, PhD
Scientific Director
Clinical Cancer Cytogenetics

Sunita D. Nasta, MD
Assistant Professor, Medicine
Division of Hematology Oncology

Alexander Perl, MD
Assistant Professor, Medicine
Division of Hematology Oncology

Ran Reshef, MD
Assistant Professor, Medicine
Division of Hematology Oncology

Jakub Svoboda, MD
Assistant Professor, Medicine
Division of Hematology Oncology

Dan Vogl, MD
Assistant Professor, Medicine
Division of Hematology Oncology

Brendan M. Weiss, MD
Assistant Professor, Medicine
Division of Hematology Oncology

Guest Speaker
Anthony R. Mato, MD, MSCE
Director of Chronic Lymphocytic Leukemia Program
John Theurer Cancer Center
Hackensack University Medical Center
Hackensack, NJ

Nondiscrimination Statement:
The University of Pennsylvania values diversity and seeks talented students, faculty and staff from diverse backgrounds. The University of Pennsylvania does not discriminate on the basis of race, sex, sexual orientation, religion, gender identity, color, national or ethnic origin, age, disability, or status as a Vietnam Era Veteran or disabled veteran in the administration of educational policies, programs or activities; admissions policies; scholarship and loan awards; athletic, or other University administered programs or employment. Questions or complaints regarding this policy should be directed to: Executive Director, Office of Affirmative Action and Equal Opportunity Programs, 3600 Chestnut Street, Samson Place East, Suite 228, Philadelphia, PA 19104-6106. Or 215-898-6993 (Voice) or 215-898-7803 (TDD).
Update in Hematologic Cancers
with Proceedings from International Medical Meetings

Accreditation:

Physicians: The Perelman School of Medicine at the University of Pennsylvania is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Nurses & Social Workers: The Leukemia & Lymphoma Society is approved by the California State Board of Nursing as a provider of Continuing Education for Registered Nurses and is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education Program.

Designation of Credit:

Physicians: The Perelman School of Medicine at the University of Pennsylvania designates this live activity for a maximum of 6.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses & Social Workers: Approval for nurses has been obtained by the National Office of the Leukemia & Lymphoma Society under provider number CEP 5832 to award 6.25 continuing education hours through the California Board of Registered Nursing. Approval for social workers has been obtained by the Leukemia & Lymphoma Society’s National Office under provider #1105 to award 6.25 continuing education hours through the Association of Social Work Boards.

AAPA: AAPA accepts certificates of participation for educational activities certified for Category 1 credit from AOACCME, prescribed credit from AAFP, and AMA PRA Category 1 Credit™.

Disclosures:

The Perelman School of Medicine at the University of Pennsylvania, Office of Continuing Medical Education, adheres to the ACCME Standards for Commercial Support. Faculty disclosure information will be made available in the conference materials and syllabi. Faculty members are also expected to disclose to participants any discussion of off-label and/or investigational use of pharmaceutical products or devices within their presentations.

Please check the box which applies:

☐ $100 | Practicing Physician
☐ $50 | Non-Pen Resident, Fellow, Nurse, and other healthcare professional
☐ $0 | Faculty, Staff, Resident, Fellow and/or Student of the University of Pennsylvania

Mail or fax registration to:
Mary M. Graham at Penn Medicine, Marketing
Abramson Cancer Center of the University of Pennsylvania
3600 Market Street – Suite 210
Philadelphia, PA 19104-2643
Fax: 215-614-0945

Credit Card Payments: For security purposes, please register online at PennCancer.org/CME/Blood if you are paying with a credit card. We accept Visa, Discover, MasterCard, and American Express.

Make checks payable to:
Trustees, University of Pennsylvania

(Registration includes breakfast, lunch, breaks and course syllabus)
UPDATE IN HEMATOLOGIC CANCERS
with Proceedings from International Medical Meetings

CME/CE - CERTIFIED COURSE

FRIDAY, FEBRUARY 7, 2014
8:00 A.M. – 4:15 P.M.